tiprankstipranks
Trending News
More News >
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
Advertisement

Benitec Biopharma (BNTC) AI Stock Analysis

Compare
297 Followers

Top Page

BNTC

Benitec Biopharma

(NASDAQ:BNTC)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
$12.50
▼(-11.28% Downside)
Benitec Biopharma's stock score is primarily driven by weak financial performance, reflected in large net losses and negative cash flow. The technical outlook is bearish, and valuation concerns arise from a negative P/E ratio. However, the recent positive corporate event provides a glimmer of potential growth, slightly boosting the score.
Positive Factors
Clinical Advancement
The advancement of the BB-301 clinical study with positive safety results is a promising development, potentially improving market position and offering strategic growth prospects.
Strong Equity Position
A strong equity position with minimal leverage provides financial stability, reducing risk and offering a solid foundation for future growth initiatives.
Proprietary Technology
The proprietary ddRNAi technology offers a unique competitive advantage in gene therapy, potentially leading to breakthrough treatments and partnerships.
Negative Factors
Negative Cash Flow
Negative cash flow indicates ongoing cash burn, which could limit the company's ability to fund operations and strategic initiatives without additional financing.
Declining Revenue
Inconsistent revenue growth and significant net losses reflect challenges in generating sales, impacting the company's ability to achieve sustainable profitability.
Negative Margins
Negative profit margins highlight operational inefficiencies and financial challenges, which could hinder long-term viability and investor confidence.

Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)

Benitec Biopharma Business Overview & Revenue Model

Company DescriptionBenitec Biopharma (BNTC) is a biotechnology company focused on developing therapeutic solutions using its proprietary DNA-directed RNA interference (ddRNAi) technology. This technology aims to silence disease-causing genes, offering a novel approach to treating a range of genetic disorders. The company's core focus areas include orphan diseases, infectious diseases, and oncology.
How the Company Makes MoneyBenitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary
Benitec Biopharma's financial performance is weak, with significant net losses, negative cash flow, and inconsistent revenue growth. Despite a strong equity position and recent financing, the company's financial instability poses substantial risks.
Income Statement
20
Very Negative
The income statement shows a declining revenue trend with a significant net loss and negative margins. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of -2916.67%, a net profit margin of -356916.67%, and an EBIT margin of -401550%. Revenue growth is inconsistent, showing a decline compared to previous periods, reflecting challenges in generating sales.
Balance Sheet
50
Neutral
Benitec Biopharma's balance sheet shows a strong equity position with an equity ratio of 96.11% in TTM. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage. The return on equity is negative, reflecting ongoing net losses. The company maintains a robust cash position, providing some stability.
Cash Flow
30
Negative
The cash flow statement highlights negative operating cash flow and free cash flow in TTM. The free cash flow growth rate is negative, indicating cash burn. However, the company raised substantial financing, improving liquidity. The operating cash flow to net income ratio is close to 1, suggesting cash flow issues align with net losses.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue556.00K0.00216.00K75.00K73.00K59.00K
Gross Profit0.00-396.00K108.00K-306.00K64.00K-64.00K
EBITDA-41.77M-41.77M-21.41M-19.15M-17.85M-13.45M
Net Income-37.92M-37.92M-21.75M-19.56M-18.21M-13.88M
Balance Sheet
Total Assets99.59M99.59M52.21M4.46M5.97M21.38M
Cash, Cash Equivalents and Short-Term Investments97.74M97.74M50.87M2.48M4.06M19.77M
Total Debt849.00K849.00K284.00K559.00K811.00K213.00K
Total Liabilities2.30M2.30M4.96M4.26M3.09M1.37M
Stockholders Equity97.30M97.30M47.25M202.00K2.88M20.01M
Cash Flow
Free Cash Flow-23.59M-23.61M-19.58M-18.01M-15.91M-13.05M
Operating Cash Flow-23.59M-23.59M-19.40M-18.01M-15.90M-12.83M
Investing Cash Flow-6.00K-18.00K-179.00K-1.00K-13.00K-221.00K
Financing Cash Flow70.48M70.48M68.03M16.02M0.0022.52M

Benitec Biopharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price14.09
Price Trends
50DMA
12.62
Positive
100DMA
13.40
Positive
200DMA
12.85
Positive
Market Momentum
MACD
0.24
Positive
RSI
58.38
Neutral
STOCH
44.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Positive. The current price of 14.09 is above the 20-day moving average (MA) of 13.67, above the 50-day MA of 12.62, and above the 200-day MA of 12.85, indicating a bullish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 58.38 is Neutral, neither overbought nor oversold. The STOCH value of 44.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTC.

Benitec Biopharma Risk Analysis

Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Benitec Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
534.47M-129.50-15.65%85.40%40.95%
60
Neutral
830.75M-2.48131.84%1049.81%7.85%
58
Neutral
854.00M-4.79-50.24%
57
Neutral
1.48B-5.55-183.14%-100.08%-2.45%
47
Neutral
$354.64M-42.31%83.28%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BNTC
Benitec Biopharma
14.09
4.86
52.65%
CKPT
Checkpoint Therapeutics
4.26
2.01
89.33%
ETON
Eton Pharmaceuticals
19.93
14.13
243.62%
PHAT
Phathom Pharmaceuticals
11.71
-5.81
-33.16%
AMLX
Amylyx Pharmaceuticals Inc
13.88
10.80
350.65%
ZBIO
Zenas BioPharma, Inc.
20.28
3.14
18.32%

Benitec Biopharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Benitec Biopharma Advances BB-301 Clinical Study
Positive
Jul 9, 2025

On July 9, 2025, Benitec Biopharma announced that the sixth and final subject of Cohort 1 was safely treated with a low dose of BB-301 in their Phase 1b/2a Clinical Treatment Study. Following a positive recommendation from the Data Safety Monitoring Board, the company plans to begin enrolling subjects for Cohort 2 in the fourth quarter of 2025. This development marks a significant step in advancing their gene therapy program, potentially enhancing Benitec’s position in the biotechnology industry and offering hope for stakeholders involved in the treatment of OPMD.

The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025